Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of analyst coverage. GLP-1 adoption has fueled Lilly’s differentiated growth profile, but additional growth drivers could add momentum, the analyst tells investors in a research note. The firm expects label expansion of tirzepatide beyond diabetes and obesity to sleep apnea and heart failure in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk’s (NYSE:NVO) GLP-1 Drugs Could Help Fight Alzheimer’s Disease
- Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports
- Eli Lilly announces MHRA grants marketing authorization for donanemab
- GE Aerospace, GM report quarterly earnings beats: Morning Buzz
- Pfizer, Lilly pressed about telehealth prescriber relationships, STAT reports